ATE135587T1 - Kombination von igf-i und igfbp für den aufbaustoffwechsel (anabolismus) - Google Patents

Kombination von igf-i und igfbp für den aufbaustoffwechsel (anabolismus)

Info

Publication number
ATE135587T1
ATE135587T1 AT92903897T AT92903897T ATE135587T1 AT E135587 T1 ATE135587 T1 AT E135587T1 AT 92903897 T AT92903897 T AT 92903897T AT 92903897 T AT92903897 T AT 92903897T AT E135587 T1 ATE135587 T1 AT E135587T1
Authority
AT
Austria
Prior art keywords
igf
combination
igfbp
mammal
anabolism
Prior art date
Application number
AT92903897T
Other languages
English (en)
Inventor
Ross G Clark
Venkat R Mukku
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24624851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE135587(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE135587T1 publication Critical patent/ATE135587T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Package Frames And Binding Bands (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT92903897T 1991-02-12 1992-01-13 Kombination von igf-i und igfbp für den aufbaustoffwechsel (anabolismus) ATE135587T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/654,436 US5187151A (en) 1991-02-12 1991-02-12 Use of binding protein with igf-i as an anabolic growth promoting agent

Publications (1)

Publication Number Publication Date
ATE135587T1 true ATE135587T1 (de) 1996-04-15

Family

ID=24624851

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92903897T ATE135587T1 (de) 1991-02-12 1992-01-13 Kombination von igf-i und igfbp für den aufbaustoffwechsel (anabolismus)

Country Status (10)

Country Link
US (1) US5187151A (de)
EP (1) EP0571417B1 (de)
JP (1) JPH06505235A (de)
AT (1) ATE135587T1 (de)
CA (1) CA2101340C (de)
DE (1) DE69209277T2 (de)
DK (1) DK0571417T3 (de)
ES (1) ES2085001T3 (de)
GR (1) GR3019851T3 (de)
WO (1) WO1992013556A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
DK0661990T3 (da) * 1992-08-26 2002-06-17 Celtrix Pharma Fremgangsmåde til systemisk behandling af kataboliske tilstande og systemisk vævsbeskadigelse
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
DE69332026T2 (de) * 1992-10-29 2002-10-31 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
TJ286B (en) * 1992-10-29 2000-12-13 Genentech Inc A method for treatment or prevention of obesity
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
WO1994016723A2 (en) * 1993-01-29 1994-08-04 Synergen, Inc. Wound healing composition
US5459051A (en) * 1993-03-26 1995-10-17 Celtrix Pharmaceuticals, Inc. Methods and vectors for over-expression of ubiquitin fusion proteins in host cells
DE69434403T2 (de) * 1993-09-20 2006-05-04 Celtrix Pharmaceuticals, Inc. Behandlung von immunologischen und hämatologischen Störungen mit IGFBP allein oder als Komplex mit IGF
AU693489B2 (en) * 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
CA2195474A1 (en) * 1994-07-20 1996-02-01 Cedo Martin Bagi Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
AUPN271195A0 (en) * 1995-05-02 1995-05-25 Bunge Meat Industries Ltd. Method of selecting livestock
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP0766966A3 (de) * 1995-09-08 2001-02-28 Eli Lilly And Company Methode zur Behandlung der Insulinresistenz
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
US5747273A (en) * 1996-05-07 1998-05-05 Diagnostic Systems Laboratories, Inc. Immunoassay of total insulin-like growth factor binding protein-1
AUPN999096A0 (en) * 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6066464A (en) * 1996-12-10 2000-05-23 Diagnostic Systems Laboratories, Inc. Immunoassay of IGF family of peptides, their binding proteins and related molecules in dried whole blood filter paper spots
US5824467A (en) * 1997-02-25 1998-10-20 Celtrix Pharmaceuticals Methods for predicting drug response
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
WO1998050428A1 (en) * 1997-05-05 1998-11-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6548482B1 (en) 1997-05-05 2003-04-15 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
EP1117425A2 (de) * 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Verfahren zur behandlung von nichtthyroidstörungen
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
ATE389416T1 (de) * 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
CA2422625A1 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
US6861406B2 (en) * 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
EP2274978B1 (de) 2003-09-12 2015-05-20 Tercica, Inc. Verfahren zur Behandlung von IGF-1 (insulin-like growth factor 1)-Mangel
JP2008511838A (ja) * 2004-08-30 2008-04-17 テルシカ・インク インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
US8518877B2 (en) * 2007-04-18 2013-08-27 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
WO2017117236A1 (en) 2015-12-31 2017-07-06 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate
JP7077229B2 (ja) * 2015-12-31 2022-05-30 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッド 非組み換えヒトインスリン様成長因子結合タンパク質の濃縮物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1163880B (it) * 1983-07-29 1987-04-08 Guido Vergari Fascetta di legatura
ATE81779T1 (de) * 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
ATE90690T1 (de) * 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) * 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
DE3822646A1 (de) * 1988-07-05 1990-01-11 Steag Ag Verfahren zur gewinnung von sphaerischen feststoffteilchen insbesondere solchen zur verwendung als strahlperlen
CA1341598C (en) * 1988-07-15 2009-09-29 Central Sydney Area Health Service Acid-labile sub-unit (als) of insulin-like growth factor binding proteincomplex
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides

Also Published As

Publication number Publication date
DK0571417T3 (da) 1996-04-15
DE69209277D1 (de) 1996-04-25
EP0571417A1 (de) 1993-12-01
JPH06505235A (ja) 1994-06-16
GR3019851T3 (en) 1996-08-31
CA2101340C (en) 2003-05-06
DE69209277T2 (de) 1996-10-31
CA2101340A1 (en) 1992-08-13
EP0571417B1 (de) 1996-03-20
US5187151A (en) 1993-02-16
ES2085001T3 (es) 1996-05-16
WO1992013556A1 (en) 1992-08-20

Similar Documents

Publication Publication Date Title
ATE135587T1 (de) Kombination von igf-i und igfbp für den aufbaustoffwechsel (anabolismus)
CA2083159A1 (en) The combination of growth hormone and insulin-like growth factor-1 enhances growth
DE69219607D1 (de) Verfahren zur anregung der immunresponz
Dempsey et al. The experimental induction of oestrus (sexual receptivity) in the normal and ovariectomized guinea pig
US5589457A (en) Process for the synchronization of ovulation
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
PT82978B (pt) Processo para a producao de hormonas de crescimento recombinantes bio-activas secas
SE9100242D0 (sv) Saett att mjoelka
ATE343395T1 (de) Verfahren zur verabreichung von igf-1
Singhas et al. Hormonal control of the tail fin and of the nuptial pads in the male red-spotted newt
Dubreuil et al. Influence of age and sex on basal secretion of growth hormone (GH) and on GH-induced release by porcine GH-releasing factor pGRF (1–29NH2) in growing pigs
PT98711A (pt) Metodo para a preparacao de alaglu-igf-1 e para a sua renaturacao e metodo para a preparacao de igf-1 humano
AR004124A1 (es) Proceso para la preparacion de un secretagogo de hormona de crecimiento.
DE69417397D1 (de) Lösung, die igf-1 enthält
Das et al. Responses of ovaries of immature chickens to avian and mammalian gonadotrophins
RO82047B (ro) Procedeu de stimulare a ovulatiei la animale femele
CS151887A2 (en) Method of sound, physiologically normal farming animal's mamma parenchyma's growth increase
MY100892A (en) Veterinary preparations.
Anderson Lactogenic hormone requirement for pseudopregnancy in normal and hysterectomized rats
DE69131629D1 (de) Behandlung fehlender milchabsonderung beim menschen
SE8501202D0 (sv) Human intestinal hormone and its use
ATE153859T1 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder
ES2097816T5 (es) Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes.
ES2010718A6 (es) Un metodo para preparar una composicion de pienso para animales que contiene salbutamol.
ATE59779T1 (de) Verfahren zur regulierung der tierischen fortpflanzung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time